Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

Hady Ghanem, Guillermo Garcia Manero, Stefan Faderl, Farhad Ravandi, Jorge Cortes, Lakshmikanth Katragadda, Susan O'brien, Naval Daver, Sherry Pierce, Tapan Kadia, Hagop Kantarjian, Elias Jabbour

Research output: Contribution to journalArticle

Abstract

Background: The outcome of patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) post clofarabine is unknown. Methods: We reviewed 109 patients with MDS or CMML with a median age of 67 years, treated with a clofarabine-based chemotherapy as frontline (n = 38) or salvage (n = 71) therapy. A total of 58 (53%) patients received salvage therapy after clofarabine failure: 13 allogeneic stem cell transplant (ASCT), 18 high-dose cytarabine-containing regimen, 10 hypomethylating agents and 17 investigational treatments. Results: Eight patients achieved complete remission (CR) and three had stable disease for an overall response rate of 19%. With a median follow-up of 3 months from clofarabine failure, 12 patients (11%) remained alive, 5 remain in CR, 4 of them after ASCT. The median overall survival post clofarabine failure was 4 months with a 1-year survival rate of 23%. This outcome is predictable, with patients with high-risk disease at the time of clofarabine failure having the worse survival. To date, patients with MDS continue to have a short survival after failure of all available therapies. Ultimately, patients who are candidates for additional treatments should be offered novel approaches. In conclusion, the outcome of patients with MDS and CMML post clofarabine failure is poor. The pattern is similar to patients with MDS post hypomethylating agent failure and predictable using University of Texas M. D. Anderson Cancer Center global scoring system.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalTherapeutic Advances in Hematology
Volume5
Issue number2
DOIs
StatePublished - Apr 2014
Externally publishedYes

Fingerprint

Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Survival
Stem Cells
clofarabine
Transplants
Salvage Therapy
Investigational Therapies
Cytarabine
Therapeutics
Survival Rate

Keywords

  • chronic myelomonocytic leukemia
  • clofarabine
  • myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. / Ghanem, Hady; Garcia Manero, Guillermo; Faderl, Stefan; Ravandi, Farhad; Cortes, Jorge; Katragadda, Lakshmikanth; O'brien, Susan; Daver, Naval; Pierce, Sherry; Kadia, Tapan; Kantarjian, Hagop; Jabbour, Elias.

In: Therapeutic Advances in Hematology, Vol. 5, No. 2, 04.2014, p. 29-34.

Research output: Contribution to journalArticle

Ghanem, H, Garcia Manero, G, Faderl, S, Ravandi, F, Cortes, J, Katragadda, L, O'brien, S, Daver, N, Pierce, S, Kadia, T, Kantarjian, H & Jabbour, E 2014, 'Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure', Therapeutic Advances in Hematology, vol. 5, no. 2, pp. 29-34. https://doi.org/10.1177/2040620713519742
Ghanem, Hady ; Garcia Manero, Guillermo ; Faderl, Stefan ; Ravandi, Farhad ; Cortes, Jorge ; Katragadda, Lakshmikanth ; O'brien, Susan ; Daver, Naval ; Pierce, Sherry ; Kadia, Tapan ; Kantarjian, Hagop ; Jabbour, Elias. / Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. In: Therapeutic Advances in Hematology. 2014 ; Vol. 5, No. 2. pp. 29-34.
@article{8f17111afc0a449b8953f567340011f6,
title = "Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure",
abstract = "Background: The outcome of patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) post clofarabine is unknown. Methods: We reviewed 109 patients with MDS or CMML with a median age of 67 years, treated with a clofarabine-based chemotherapy as frontline (n = 38) or salvage (n = 71) therapy. A total of 58 (53{\%}) patients received salvage therapy after clofarabine failure: 13 allogeneic stem cell transplant (ASCT), 18 high-dose cytarabine-containing regimen, 10 hypomethylating agents and 17 investigational treatments. Results: Eight patients achieved complete remission (CR) and three had stable disease for an overall response rate of 19{\%}. With a median follow-up of 3 months from clofarabine failure, 12 patients (11{\%}) remained alive, 5 remain in CR, 4 of them after ASCT. The median overall survival post clofarabine failure was 4 months with a 1-year survival rate of 23{\%}. This outcome is predictable, with patients with high-risk disease at the time of clofarabine failure having the worse survival. To date, patients with MDS continue to have a short survival after failure of all available therapies. Ultimately, patients who are candidates for additional treatments should be offered novel approaches. In conclusion, the outcome of patients with MDS and CMML post clofarabine failure is poor. The pattern is similar to patients with MDS post hypomethylating agent failure and predictable using University of Texas M. D. Anderson Cancer Center global scoring system.",
keywords = "chronic myelomonocytic leukemia, clofarabine, myelodysplastic syndrome",
author = "Hady Ghanem and {Garcia Manero}, Guillermo and Stefan Faderl and Farhad Ravandi and Jorge Cortes and Lakshmikanth Katragadda and Susan O'brien and Naval Daver and Sherry Pierce and Tapan Kadia and Hagop Kantarjian and Elias Jabbour",
year = "2014",
month = "4",
doi = "10.1177/2040620713519742",
language = "English (US)",
volume = "5",
pages = "29--34",
journal = "Therapeutic Advances in Hematology",
issn = "2040-6207",
number = "2",

}

TY - JOUR

T1 - Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

AU - Ghanem, Hady

AU - Garcia Manero, Guillermo

AU - Faderl, Stefan

AU - Ravandi, Farhad

AU - Cortes, Jorge

AU - Katragadda, Lakshmikanth

AU - O'brien, Susan

AU - Daver, Naval

AU - Pierce, Sherry

AU - Kadia, Tapan

AU - Kantarjian, Hagop

AU - Jabbour, Elias

PY - 2014/4

Y1 - 2014/4

N2 - Background: The outcome of patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) post clofarabine is unknown. Methods: We reviewed 109 patients with MDS or CMML with a median age of 67 years, treated with a clofarabine-based chemotherapy as frontline (n = 38) or salvage (n = 71) therapy. A total of 58 (53%) patients received salvage therapy after clofarabine failure: 13 allogeneic stem cell transplant (ASCT), 18 high-dose cytarabine-containing regimen, 10 hypomethylating agents and 17 investigational treatments. Results: Eight patients achieved complete remission (CR) and three had stable disease for an overall response rate of 19%. With a median follow-up of 3 months from clofarabine failure, 12 patients (11%) remained alive, 5 remain in CR, 4 of them after ASCT. The median overall survival post clofarabine failure was 4 months with a 1-year survival rate of 23%. This outcome is predictable, with patients with high-risk disease at the time of clofarabine failure having the worse survival. To date, patients with MDS continue to have a short survival after failure of all available therapies. Ultimately, patients who are candidates for additional treatments should be offered novel approaches. In conclusion, the outcome of patients with MDS and CMML post clofarabine failure is poor. The pattern is similar to patients with MDS post hypomethylating agent failure and predictable using University of Texas M. D. Anderson Cancer Center global scoring system.

AB - Background: The outcome of patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) post clofarabine is unknown. Methods: We reviewed 109 patients with MDS or CMML with a median age of 67 years, treated with a clofarabine-based chemotherapy as frontline (n = 38) or salvage (n = 71) therapy. A total of 58 (53%) patients received salvage therapy after clofarabine failure: 13 allogeneic stem cell transplant (ASCT), 18 high-dose cytarabine-containing regimen, 10 hypomethylating agents and 17 investigational treatments. Results: Eight patients achieved complete remission (CR) and three had stable disease for an overall response rate of 19%. With a median follow-up of 3 months from clofarabine failure, 12 patients (11%) remained alive, 5 remain in CR, 4 of them after ASCT. The median overall survival post clofarabine failure was 4 months with a 1-year survival rate of 23%. This outcome is predictable, with patients with high-risk disease at the time of clofarabine failure having the worse survival. To date, patients with MDS continue to have a short survival after failure of all available therapies. Ultimately, patients who are candidates for additional treatments should be offered novel approaches. In conclusion, the outcome of patients with MDS and CMML post clofarabine failure is poor. The pattern is similar to patients with MDS post hypomethylating agent failure and predictable using University of Texas M. D. Anderson Cancer Center global scoring system.

KW - chronic myelomonocytic leukemia

KW - clofarabine

KW - myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84993709510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993709510&partnerID=8YFLogxK

U2 - 10.1177/2040620713519742

DO - 10.1177/2040620713519742

M3 - Article

AN - SCOPUS:84993709510

VL - 5

SP - 29

EP - 34

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

SN - 2040-6207

IS - 2

ER -